← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Myogene Bio, Llc
San Diego, CA
$3,772,804
Total funding
6
Grants
Funding over time
peak $2.3M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,772,804 · 6
By mechanism
R44$2,509,835 · 2
R21$613,750 · 2
SB1$499,300 · 1
R43$149,919 · 1
Investigators at Myogene Bio, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy$1,321,604
R44 · FY2025 · NS
Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy$499,300
SB1 · FY2025 · AR
Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$499,207
R44 · FY2022 · AR
Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$493,728
R44 · FY2020 · AR
Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophy$302,500
R21 · FY2025 · HD
Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy$201,250
R21 · FY2025 · TR
Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$195,296
R44 · FY2019 · AR
Comparison of single versus dual vector delivery of AAV-SPY-DYS45-55 for Duchenne muscular dystrophy$149,919
R43 · FY2020 · AR
Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy$110,000
R21 · FY2024 · TR